Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:43 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,625 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Genetics Clear all
Completed Phase 1 Interventional

Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)

NCT00352599
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Lovastatin, placebo pill
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
10 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Nov 1, 2026, 10:43 PM EST
Withdrawn Not applicable Interventional

Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery

NCT04344626
View directory record Official record
Conditions
Epilepsy, Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly, Polymicrogyria, Rasmussen Encephalitis, Sturge-Weber Syndrome, Gliosis, Stroke, Tumor, Brain
Interventions
Intra-operative brain tonometry
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Nov 1, 2026, 10:43 PM EST
Completed Phase 1 Interventional

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

NCT01445418
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
AZ2281 + Carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Nov 1, 2026, 10:43 PM EST
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Nov 1, 2026, 10:43 PM EST
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

NCT00379340
View directory record Official record
Conditions
Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions
3-Dimensional Conformal Radiation Therapy, Conventional Surgery, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Vincristine Sulfate Liposome
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
199
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 1, 2026, 10:43 PM EST
Recruiting Phase 1Phase 2 Interventional

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

NCT05442515
View directory record Official record
Conditions
B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, B-precursor ALL, B-All, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia, Acute Lymphoid Leukemia
Interventions
CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 39 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 10:43 PM EST
Completed Not applicable Interventional

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

NCT06534424
View directory record Official record
Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Interventions
Best Practice, Biospecimen Collection, Counseling, Discussion, Genotyping, Molecular Risk Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Nov 1, 2026, 10:43 PM EST
Completed Phase 1 Interventional Results available

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

NCT01742286
View directory record Official record
Conditions
ALK-activated Tumors
Interventions
Ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Nov 1, 2026, 10:43 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

NCT00690469
View directory record Official record
Conditions
Extraocular Retinoblastoma, Intraocular Retinoblastoma, Recurrent Retinoblastoma
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
49
States / cities
Los Angeles, California • Madera, California • San Francisco, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Nov 1, 2026, 10:43 PM EST
Active, not recruiting Not applicable Interventional

Home Based Tele-exercise for People With Chronic Neurological Impairments

NCT04564495
View directory record Official record
Conditions
Neurologic Disorder, Stroke, Spinal Cord Injuries, Cerebral Palsy, Hemiplegia, Hemiparesis, Multiple Sclerosis, Parkinson Disease, Trauma, Brain, Transverse Myelitis, Friedreich Ataxia
Interventions
Seated exercise
Behavioral
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Nov 1, 2026, 10:43 PM EST
Completed Phase 1 Interventional

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT00892736
View directory record Official record
Conditions
Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Nov 1, 2026, 10:43 PM EST
Completed Phase 1 Interventional

First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors

NCT02160106
View directory record Official record
Conditions
Advanced Stage Solid Tumors
Interventions
TEW-7197
Drug
Lead sponsor
MedPacto, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Nov 1, 2026, 10:43 PM EST
Recruiting No phase listed Observational

Study of Skin Tumors in Tuberous Sclerosis

NCT00001975
View directory record Official record
Conditions
Tuberous Sclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 10:43 PM EST
Completed No phase listed Observational

Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer

NCT01386411
View directory record Official record
Conditions
Breast Cancer
Interventions
BRCA testing and questionnaire assessments
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Nov 1, 2026, 10:43 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer

NCT03922893
View directory record Official record
Conditions
Cancer
Interventions
Family History Information, ORAGENE, Blood, Skin Biopsy
Other · Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 1, 2026, 10:43 PM EST
Completed No phase listed Observational

Identification of Prostate Cancer Genes

NCT00342784
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Nov 1, 2026, 10:43 PM EST
Completed No phase listed Observational

Development and Validation of an Online Neurobehavioral Evaluation Tool for PTEN Patients

NCT05671107
View directory record Official record
Conditions
PTEN Hamartoma Tumor Syndrome
Interventions
NET
Diagnostic Test
Lead sponsor
John Carroll University
Other
Eligibility
3 Years to 45 Years
Enrollment
300 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
University Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 1, 2026, 10:43 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®
Biological · Drug
Lead sponsor
Nouscom SRL
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 1, 2026, 10:43 PM EST
Recruiting Phase 1 Interventional

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

NCT06357182
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Biopsy, Echocardiography Test, Iadademstat, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 1, 2026, 10:43 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome

NCT07106359
View directory record Official record
Conditions
Cascade Testing, Lynch Syndrome, Decision Making, Colorectal Cancer, Uterine Cancer, Cancer Prevention
Interventions
Information Letter and Booklet, Information Letter
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 1, 2026, 10:43 PM EST
Completed No phase listed Observational

Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia

NCT01284010
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, fluorescence in situ hybridization, gene expression analysis, microarray analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Nov 1, 2026, 10:43 PM EST
Completed No phase listed Observational

Registry of Mastectomy for Breast Cancer Risk Reduction

NCT00555503
View directory record Official record
Conditions
Quality of Life, Mastectomy, Breast Neoplasms, Genetic Predisposition to Disease, Adjustment Disorder
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Nov 1, 2026, 10:43 PM EST
Completed Phase 2 Interventional Results available

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

NCT02614794
View directory record Official record
Conditions
HER2 Positive Breast Cancer
Interventions
tucatinib, capecitabine, trastuzumab, placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 1, 2026, 10:43 PM EST
Completed Phase 2 Interventional Results available

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00248495
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, pemetrexed disodium, adjuvant therapy, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Nov 1, 2026, 10:43 PM EST